MétaCan
Menu
Back to cohort
Record W3030494473 · doi:10.1200/jco.20.00158

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients

2020· article· en· W3030494473 on OpenAlexafffund
Thomas Lehrnbecher, Brian T. Fisher, Bob Phillips, Melissa Beauchemin, Fabianne Carlesse, Elio Castagnola, Nathan Duong, L. Lee Dupuis, Vicky Fioravantti, Andreas H. Groll, Gabrielle M. Haeusler, Emmanuel Roilides, Michelle Science, William J. Steinbach, Wim J. E. Tissing, Adilia Warris, Priya Patel, Paula D. Robinson, Lillian Sung

Bibliographic record

VenueJournal of Clinical Oncology · 2020
Typearticle
Languageen
FieldMedicine
TopicAntifungal resistance and susceptibility
Canadian institutionsInstitute for Clinical Evaluative SciencesPediatric Oncology GroupSickKids FoundationUniversity of TorontoHospital for Sick ChildrenPrincess Margaret Cancer Centre
FundersMedical Research CouncilUniversity of ExeterAstellas PharmaWellcome TrustNational Institute for Health and Care ResearchGilead SciencesPediatric Oncology Group of OntarioPfizer
KeywordsMedicinePosaconazoleEchinocandinVoriconazoleGuidelineIntensive care medicineTransplantationHematopoietic stem cell transplantationItraconazoleImmunosuppressionCancerInternal medicineAntifungalFluconazoleDermatology

Abstract

fetched live from OpenAlex

PURPOSE: To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. METHODS: Recommendations were developed by an international multidisciplinary panel that included a patient advocate. We conducted a systematic review of systemic antifungal prophylaxis in children and adults with cancer and HSCT recipients. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to make strong or weak recommendations and to classify level of evidence as high, moderate, low, or very low. The panel considered directness of the data to pediatric patients. RESULTS: There were 68 randomized trials included in the systematic review, of which 6 (9%) were conducted in a solely pediatric population. Strong recommendations were made to administer systemic antifungal prophylaxis to children and adolescents receiving treatment of acute myeloid leukemia, to those undergoing allogeneic HSCT pre-engraftment, and to those receiving systemic immunosuppression for graft-versus-host disease treatment. A strong recommendation was made to administer a mold-active agent with an echinocandin or a mold-active azole when systemic antifungal prophylaxis is warranted. For children younger than 13 years of age, an echinocandin, voriconazole, or itraconazole is suggested. Posaconazole may also be used in those age 13 years or older. A strong recommendation against routine administration of amphotericin as systemic antifungal prophylaxis was made. CONCLUSION: We developed a clinical practice guideline for systemic antifungal prophylaxis administration in pediatric patients with cancer and HSCT recipients. Implementation and assessment of guideline-concordant rates and impacts are important future steps.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.022
metaresearch head score (Gemma)0.074
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.026
Threshold uncertainty score0.115

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0220.074
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.008
Bibliometrics0.0070.005
Science and technology studies0.0020.001
Scholarly communication0.0040.004
Open science0.0070.003
Research integrity0.0110.009
Insufficient payload (model declined to judge)0.0060.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.073
GPT teacher head0.438
Teacher spread0.365 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations142
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicAntifungal resistance and susceptibilityFrench-language works237,207